Douglas Michael P, Lin Grace A, Trosman Julia R, Phillips Kathryn A
UCSF Center for Translational and Policy Research On Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California San Francisco, 490 Illinois Street, 3rd Floor, Box 0613, San Francisco, CA, 94143, USA.
Department of Medicine, University of California, San Francisco, CA, USA.
J Community Genet. 2022 Feb;13(1):75-80. doi: 10.1007/s12687-021-00563-y. Epub 2021 Nov 6.
Hereditary breast and ovarian cancers (HBOCs) are common among the Latinx population, and risk testing is recommended using multi-gene hereditary cancer panels (HCPs). However, little is known about how payer reimbursement and out-of-pocket expenses impact provider ordering of HCP in the Latinx population. Our objective is to describe key challenges and possible solutions for HCP testing in the Latinx population. As part of a larger study, we conducted semi-structured interviews with key provider informants (genetic counselors, oncologist, nurse practitioner) from safety-net institutions in the San Francisco Bay Area. We used a deductive thematic analysis approach to summarize themes around challenges and possible solutions to facilitating HCP testing in Latinx patients. We found few financial barriers for HCP testing for the Latinx population due to laboratory patient assistance programs that cover testing at low or no cost to patients. However, we found potential challenges related to the sustainability of low-cost testing and out-of-pocket expenses for patients, access to cascade testing for family members, and pathogenic variants specific to Latinx. Providers questioned whether current laboratory payment programs that decrease barriers to testing are sustainable and suggested solutions for accessing cascade testing and ensuring variants specific to the Latinx population were included in testing. The use of laboratories with payment assistance programs reduces barriers to HCP testing among the US population; however, other barriers are present that may impact testing use in the Latinx population and must be addressed to ensure equitable access to HCP testing for this population.
遗传性乳腺癌和卵巢癌(HBOCs)在拉丁裔人群中很常见,建议使用多基因遗传性癌症检测板(HCPs)进行风险检测。然而,关于医保报销和自付费用如何影响拉丁裔人群中医疗服务提供者对HCP检测的开具,我们知之甚少。我们的目标是描述拉丁裔人群中HCP检测的关键挑战和可能的解决方案。作为一项更大规模研究的一部分,我们对旧金山湾区安全网机构的关键医疗服务提供者信息提供者(遗传咨询师、肿瘤学家、执业护士)进行了半结构化访谈。我们采用了演绎主题分析方法,总结了围绕促进拉丁裔患者HCP检测的挑战和可能解决方案的主题。由于实验室患者援助计划为患者提供低成本或免费检测,我们发现拉丁裔人群进行HCP检测几乎没有经济障碍。然而,我们发现了与低成本检测的可持续性、患者的自付费用、家庭成员进行级联检测的机会以及拉丁裔特有的致病基因变异相关的潜在挑战。医疗服务提供者质疑当前降低检测障碍的实验室付费计划是否可持续,并提出了获取级联检测以及确保拉丁裔人群特有的基因变异包含在检测中的解决方案。使用有付费援助计划的实验室减少了美国人群中HCP检测的障碍;然而,其他障碍仍然存在,可能会影响拉丁裔人群的检测使用,必须加以解决,以确保该人群能够公平地获得HCP检测。